Answers are grounded in this paper and cite their sources.
Feasibility study reveals a strong correlation between APT-weighted MRI signal and 18F-choline PET uptake in adolescent CNS tumors, highlighting its potential for non-invasive metabolic monitoring.
Background Paediatric and adolescent gliomas and glioneuronal tumors remain challenging to assess non-invasively. Amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI has shown promise in adult gliomas but has not been well studied in younger patients. We conducted a feasibility study to assess whether APT-weighted signal can act as a non-invasive surrogate of tumor proliferation in adolescent CNS tumors by correlating it with 18F-choline PET uptake (SUV) as a proxy for membrane synthesis/ proliferative activity. Methods Ten adolescent patients (14–19 yrs), seven with histologically confirmed and three with radiologically suspected CNS tumors, underwent simultaneous APT CEST and 18F-choline PET-MRI. Regions of interest (ROIs) corresponding to non-enhancing, enhancing, necrotic tumor, and contralateral white matter were delineated. Mean APT-weighted signal intensity (SI) and PET SUV were extracted per ROI. Nonparametric statistics and Spearman’s correlation analyses were performed. Results APT-weighted signal was significantly elevated in enhancing, non-enhancing, and necrotic tumor ROIs compared to normal white matter (p < 0.001). 18F-choline SUV was elevated in enhancing and necrotic ROIs vs white matter, but not significantly so for non-enhancing tumor (p = 0.02). A correlation between enhancing and whole-tumor APT-weighted signal and 18F-choline SUV was seen (p < 0.001). Conclusion This pilot feasibility study demonstrates that APT-CEST MRI is technically feasible in adolescents with CNS tumors and that APT-weighted signal may reflect tumour metabolic activity. The findings are hypothesis-generating and require validation in larger, histologically homogeneous cohorts. The detection of elevated APT-weighted signal even in non-enhancing tumor regions suggests potential utility in monitoring non-contrast-enhancing disease. Larger cohorts and multimodal correlation (e.g. Ki-67, amino acid PET) are warranted to confirm and extend these findings.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: